Skip to main content
NCBI home page
BMC Cancer logoLink to BMC Cancer
. 2026 Sep 26;26:1145. doi: 10.1186/s12885-026-16993-1

Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

Kanticha Thammagul 1, Suppalux Limpiwattakee 1, Pichika Chantrathammachart 1, Teeraya Puavilai 1, Suporn Chuncharunee 1, Pimjai Niparuck 1,✉
PMCID: PMC13615626  PMID: 42800856

Correction: BMC Cancer 26, 699 (2026)

https://doi.org/10.1186/s12885-026-15997-1

Following publication of the original article, the authors identified an error in the author name of Suppalux Limpiwattakee.

The incorrect author name was: Suppalux Limpiwakee.

The correct author name is: Suppalux Limpiwattakee.

The author group has been updated above and the original article [1] has been corrected.

Reference

  • 1.Thammagul K, Limpiwattakee S, Chantrathammachart P et al. Survival of myelodysplastic syndrome patients after azacitidine therapy. BMC Cancer. 2026;26:699. 10.1186/s12885-026-15997-1. [DOI] [PMC free article] [PubMed]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES